ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 22nd Annual Healthcare Conference
WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Oppenheimer 22nd Annual Healthcare Conference at 3:55 pm ET on December 13, 2011 will be webcast live.
The webcast of this presentation can be accessed live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of the presentation will be available at the same location for one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
CONTACT: For Investors:
Carol Hausner
Executive Director, Investor Relations
and Corporate Communications
ImmunoGen, Inc.
(781) 895-0600
info@immunogen.com
For Media:
Barbara Yates
The Yates Network
(781) 258-6153